AFP and hepatocellular carcinoma: Although ALT, AST, and NLR could not be used alone as a surrogate biomarker for HBV‐HCC screening in CHB patients, our studies provided some evidence that adding ALT, AST, and NLR to AFP outperformed the diagnosis for HBV‐HCC compared with AFP alone or any other combinations.